Clinical Trials Sponsored by Alan apter

Total 1216 results

alan apter

Completed

A Clinical Research Studying Interventions for Nighttime Fears in Preschool Children

Nighttime Fears

Israel
Mohamed Elsibai Anter

Completed

Sacro-hysteropexy Using Proline Mesh Versus Mersilene Tape in Apical Prolapse (hystropexy)

Apical Prolapse

Egypt
Genfit
Naturalpha; SGS Aster S.A.S.

Completed

Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505

Cardiovascular Diseases | Metabolic Diseases | Diabetes Mellitus, Type 2 | Type 2 Diabetes | Dyslipidemia | Obese

France
Axter Therapeutics (Beijing) Co., Ltd

Recruiting

Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas

Relapsed or Refractory Non-Hodgkin's Lymphoma

China
Robin, Alan L., M.D.

Completed

IOP Changes Associated With SICS and Phako

Glaucoma | Cataract
Robin, Alan L., M.D.

Completed

Impact of Health Literacy and Other Factors on Glaucoma Patient Adherence in South India

Glaucoma | Health Literacy | Patient Noncompliance

India
Robin, Alan L., M.D.

Terminated

An Evaluation of the Ability to Train Established Glaucoma Patients Who Have Difficulty in Drop Instillation

Ocular Hypertension | Glaucoma

United States
Alan Neuromedical Technologies, LLC

Completed

Duchenne Muscular Dystrophy Clinical Trial (DMD)

Duchenne Muscular Dystrophy

United States
Robin, Alan L., M.D.

Completed

An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance

Ocular Hypertension | Glaucoma
Immutep S.A.S.
SGS Aster-Cephac (CRO)

Completed

A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321

Healthy

France
Immutep S.A.S.
SGS Aster-Cephac (CRO)

Completed

Phase I Study of IMP321 Given Alone or as an Adjuvant to a Reference Flu Antigen

Healthy

France
CoheroHealth
Lindus Health; Aptar Digital Health

Not yet recruiting

Use of Aptar Digital Health's Respiratory Disease Management Platform for Asthma

Asthma Chronic
Stanford University
Schatzberg, Alan, M.D.

Completed

Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression: OL Cohort (SAINT-TRD)

Treatment Resistant Depression

United States
Alan Katz

Completed

Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma

Liver Neoplasms

United States
Loyola University
Alan J. Wolfe

Completed

Bladder Environment: Microbiome Oxygen Relationship (BEMOR)

Urinary Incontinence | UTI's

United States
Alan Katz

Withdrawn

Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B

Pancreas Cancer | Adenocarcinoma of the Pancreas

United States
Stanford University
Schatzberg, Alan, M.D.

Completed

Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD) (Ket_Nal)

Depression

United States
ASLAN Pharmaceuticals

Recruiting

Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab

Atopic Dermatitis

United States, Canada
ASLAN Pharmaceuticals

Completed

A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours

Advanced or Metastatic Solid Tumors | Advanced or Metastatic Biliary Tract Cancer

Japan
ASLAN Pharmaceuticals

Withdrawn

Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer

Advanced or Metastatic Biliary Tract Cancer
ASLAN Pharmaceuticals

Completed

Phase 1, Randomised Double Blinded Placebo Controlled Study of ASLAN003

Healthy Volunteers

Singapore
Elan Pharmaceuticals

Completed

Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain

Pain

United States
Elan Pharmaceuticals

Terminated

A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United States, Canada
Elan Pharmaceuticals

Completed

A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects With Migraine Headache

Migraine Headache

United States
Elan Pharmaceuticals

Completed

Prialt (Ziconotide) In Severe Chronic Pain

Pain

United States
Elan Pharmaceuticals

Completed

Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.

Stroke | Multiple Sclerosis | Muscle Spasticity | Spinal Cord Injury

United States
Elan Pharmaceuticals

Terminated

Open-label Adjunctive Zonisamide for Bipolar Disorder

Bipolar Disorders
Dr. Bruce B. Allan

Completed

Study of Non-Ablative Radiofrequency Treatment for Stress Urinary Incontinence

Stress Urinary Incontinence

Canada
ASLAN Pharmaceuticals

Recruiting

Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants (FAST-AA)

Alopecia Areata

United States
ASLAN Pharmaceuticals

Completed

A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

Atopic Dermatitis

Australia, Singapore, United States
Asan Foundation

Completed

Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Inflammatory Bowel Disease

Inflammatory Bowel Diseases | Crohn Disease | Ulcerative Colitis

Korea, Republic of
ASLAN Pharmaceuticals

Completed

Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer

Biliary Tract Cancer

China
ASLAN Pharmaceuticals

Completed

Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab

Metastatic Breast Cancer

Australia, Hong Kong, Korea, Republic of, New Zealand, Philippines, Singapore, Taiwan
ASLAN Pharmaceuticals

Completed

A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours

Malignant Solid Tumour
Elan Pharmaceuticals

Terminated

A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis
Alan Richardson
Quotient Clinical

Terminated

First in Human Single Ascending Dose Study of MOR107

Safety

United Kingdom
Alan Nichol

Completed

Positron Emission Tomography (PET) With 3,4-dihydroxy-6-18F-fluoro-L-enylalanine (18F-FDOPA) Study

Cancer (High-grace Glioma)

Canada
Robin, Alan L., M.D.
Alcon Research

Unknown

Observational Study of How Patients Take Eye Drops

Glaucoma

United States
Robin, Alan L., M.D.
Alcon Research

Completed

Eye Drop Use in Glaucoma Patients Through Patient Surveys and Video Observations

Glaucoma | Conjunctivitis | Dry Eye Syndrome

United States
ASLAN Pharmaceuticals

Completed

Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States, Australia, Singapore, India, Canada, New Zealand, Dominican Republic, Poland
ASLAN Pharmaceuticals

Completed

Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)

Gastric Cancer

Estonia, Hong Kong, Korea, Republic of, Lithuania, Malaysia, Singapore, Taiwan, Thailand
ASLAN Pharmaceuticals

Completed

A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Australia, Singapore
ASLAN Pharmaceuticals

Terminated

Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC

Biliary Tract Cancer

Taiwan, Korea, Republic of, Singapore
Asan Foundation

Completed

A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease

Alzheimer Disease

Korea, Republic of
ASLAN Pharmaceuticals

Completed

Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine

Solid Tumor

Taiwan, Hong Kong
ASLAN Pharmaceuticals

Completed

Open, Single-dose/-Period Study to Assess Mass Balance Recovery, Metabolite Profile/Identification of 14C-Varlitinib

Healthy Volunteers

United Kingdom
ASLAN Pharmaceuticals

Completed

ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy

Cholangiocarcinoma

Taiwan, Korea, Republic of, Singapore
Asan Foundation

Completed

Safety, Pharmacokinetics, Biodistribution, and Diagnostic Performance of [18F]GP1 PET in Thromboembolism

Thromboembolism

Korea, Republic of
ASLAN Pharmaceuticals

Completed

A Phase 1, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects

Healthy Elderly Subjects (Age ≥55 Years)

Singapore
ASLAN Pharmaceuticals

Completed

A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2

Stomach Neoplasms | Gastric Cancer | Gastric Neoplasms | Cancer of Stomach | Cancer of the Stomach

Korea, Republic of

3

Subscribe